Bioactivation and reactivity research advances - 2022 year in review‡.

Journal: Drug metabolism reviews
Published Date: Aug 22, 2023

Abstract

With the 50th year mark since the launch of journal, the field of drug metabolism and bioactivation has advanced exponentially in the past decades (Guengerich 2023).This has, in a major part, been due to the continued advances across the whole spectrum of applied technologies in hardware, software, machine learning (ML), and artificial intelligence (AI). LC-MS platforms continue to evolve to support key applications in the field, and automation is also improving the accuracy, precision, and throughput of these supporting assays. In addition, sample generation and processing is being aided by increased diversity and quality of reagents and bio-matrices so that what is being analyzed is more relevant and translatable. The application of platforms (applied software, ML, and AI) is also making great strides, and in tandem with the more traditional approaches mentioned previously, is significantly advancing our understanding of bioactivation pathways and how these play a role in toxicity. All of this continues to allow the area of bioactivation to evolve in parallel with associated fields to help bring novel or improved medicines to patients with urgent or unmet needs.Shuai Wang and Cyrus Khojasteh, on behalf of the authors.

Authors

  • Shuai Wang
    Department of Intensive Care Unit, China-Japan Union Hospital of Jilin University, Changchun, China.
  • Upendra A Argikar
    Non-clinical Development, Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Lionel Cheruzel
    Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
  • Sungjoon Cho
    Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
  • Rachel D Crouch
    Department of Pharmacy and Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, TN, USA.
  • Deepika Dhaware
    DMPK and Safety Sciences, Orion Pharma, Espoo, Finland.
  • Carley J S Heck
    Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USA.
  • Kevin M Johnson
    From the Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, Thompkins East 2, New Haven, CT 06520 (K.M.J., H.E.J., Y.Z., L.H.S.); College of Electronic Information and Automation, Civil Aviation University of China, Tianjin, China (Y.Z.); Upstate Carolina Radiology PA, Spartanburg, SC (D.A.D.); and Department of Biomedical Engineering, Yale University, New Haven, Conn (L.H.S.).
  • Amit S Kalgutkar
    Medicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.
  • Lloyd King
    Quantitative Drug Discovery, UCB Biopharma UK, Slough, UK.
  • Joyce Liu
    Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bin Ma
    Key Laboratory of Beijing for Water Quality Science and Water Environment Recovery Engineering, Engineering Research Center of Beijing, Beijing University of Technology, Beijing 10024, China.
  • Hlaing Maw
    Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Grover P Miller
    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences , Little Rock, Arkansas 72205, United States.
  • Herana Kamal Seneviratne
    Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, USA.
  • Ryan H Takahashi
    Denali Therapeutics, South San Francisco, CA, USA.
  • Cong Wei
    Drug Metabolism and Pharmacokinetics, Biogen Inc., Cambridge, MA, USA.
  • S Cyrus Khojasteh
    Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.

Keywords

External Resources

Popular Topics
Recent Journals